Bristol-Myers Squibb (NYSE:BMY) Stock Position Lifted by AXS Investments LLC

AXS Investments LLC boosted its stake in shares of Bristol-Myers Squibb (NYSE:BMYFree Report) by 25.2% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 25,298 shares of the biopharmaceutical company’s stock after purchasing an additional 5,088 shares during the period. AXS Investments LLC’s holdings in Bristol-Myers Squibb were worth $1,298,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in BMY. Milestone Investment Advisors LLC purchased a new position in Bristol-Myers Squibb during the third quarter valued at approximately $27,000. Northwest Financial Advisors purchased a new position in Bristol-Myers Squibb during the fourth quarter valued at approximately $27,000. Pacific Capital Wealth Advisors Inc. acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $34,000. Turtle Creek Wealth Advisors LLC acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $40,000. Finally, Wetzel Investment Advisors Inc. acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $40,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Stock Performance

Bristol-Myers Squibb stock traded up $0.04 on Friday, hitting $41.58. The company’s stock had a trading volume of 10,032,337 shares, compared to its average volume of 15,448,540. The company has a fifty day moving average price of $48.02 and a 200-day moving average price of $49.74. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. Bristol-Myers Squibb has a one year low of $41.07 and a one year high of $66.46. The firm has a market cap of $84.29 billion, a P/E ratio of -13.30, a price-to-earnings-growth ratio of 14.33 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The business had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. During the same quarter in the prior year, the firm earned $2.05 EPS. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. On average, equities analysts anticipate that Bristol-Myers Squibb will post 0.59 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Friday, April 5th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Thursday, April 4th. This represents a $2.40 annualized dividend and a yield of 5.77%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Analyst Ratings Changes

BMY has been the subject of a number of analyst reports. StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Thursday. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Redburn Atlantic cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $77.00 to $54.00 in a research note on Tuesday, February 6th. BMO Capital Markets reduced their price objective on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday, April 26th. Finally, Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $60.00.

View Our Latest Report on Bristol-Myers Squibb

About Bristol-Myers Squibb

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Featured Stories

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.